Abstract Number: 1196 • ACR Convergence 2020
Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors
Background/Purpose: Extra-articular manifestations of rheumatoid arthritis (RA), such as nodules and interstitial lung disease (ILD), portend poor outcomes and are more common in men than…Abstract Number: 1212 • ACR Convergence 2020
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in MTX-Naïve Adults with Moderately-to-Severely Active Rheumatoid Arthritis (RA)
Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active RA. Previously, we…Abstract Number: 1230 • ACR Convergence 2020
Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis
Background/Purpose: Ancient Eastern medicine has valued the Curcuma longa (turmeric) plant for its powerful medicinal properties. Curcumin is suggested to possess potent anti-inflammatory, antioxidant, antimicrobial,…Abstract Number: 1410 • ACR Convergence 2020
Resident Memory T Cells Persist in Joints of Anakinra-Treated Mice in Spontaneous Arthritis Model
Background/Purpose: Inflammatory arthritis is characterized by chronic inflammation of joints which can be suppressed with immunomodulatory therapy. However, two-thirds of patients will have an arthritis…Abstract Number: 1528 • ACR Convergence 2020
Filgotinib Inhibits Monocyte Differentiation and Pro Inflammatoly Cytokine Production in Osteoblasts
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction. Filgotinib is a selective small molecule inhibitor of JAK 1…Abstract Number: 1572 • ACR Convergence 2020
Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases
Background/Purpose: Lymphoproliferative disorders (LPD) that develop in rheumatoid arthritis (RA) patients treated with MTX (MTX-LPD) is one of the important complications for RA patients. MTX-LPD…Abstract Number: 1715 • ACR Convergence 2020
Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)
Background/Purpose: Early diagnosis and rapid initiation of DMARDs following a treat-to-target approach have made remission a realizable goal for many persons living with RA. Despite…Abstract Number: 1731 • ACR Convergence 2020
Development of a Disease Activity Index for Rheumatoid Arthritis Patients Using the HandScan
Background/Purpose: Disease activity in rheumatoid arthritis (RA) patients is usually measured by an index like DAS28,1 a composite measure consisting of 28 swollen and/or tender…Abstract Number: 1748 • ACR Convergence 2020
Effects of Abatacept and Tumor Necrosis Factor Inhibitor on the Normal Glycosylated Hemoglobin Level in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) and diabetes mellitus (DM) are associated with inflammation. Abatacept has been reported to be effective for type 1 diabetes. We aimed…Abstract Number: 1767 • ACR Convergence 2020
Maternal Peripartum Outcomes Are Similar to the General Population in Rheumatoid Arthritis Pregnancies
Background/Purpose: Data on birth outcomes to women with rheumatoid arthritis (RA) are limited and conflicting. Some studies indicate that women with well controlled RA have…Abstract Number: 1979 • ACR Convergence 2020
Participant Engagement and Adherence in an ArthritisPower Real-World Study to Capture Smartwatch and Patient-Reported Outcome Data Among Rheumatoid Arthritis Patients
Background/Purpose: Characterization of how different types of patient-generated data reflect patients’ experience is needed to guide integration of electronically collected patient-reported outcome (ePRO) measures and…Abstract Number: 2008 • ACR Convergence 2020
Should We Use Glucocorticoid in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Background/Purpose: The EULAR recommendations, updated in 20161 and 20192, propose the initiation of glucocorticoid (GC) therapy in combination with cDMARDs background therapy for every patient…Abstract Number: 0033 • ACR Convergence 2020
Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy
Background/Purpose: Pregnancy is known to have disease-modifying effects on rheumatoid arthritis (RA). A role for long non-coding (lnc) RNAs in the improvement or worsening of…Abstract Number: 0105 • ACR Convergence 2020
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF)…Abstract Number: 0152 • ACR Convergence 2020
Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals
Background/Purpose: Understanding patient goals and concerns is essential for aligning treatment decisions with patient preferences and supporting effective patient-clinician partnerships. Yet, little is known about…
- « Previous Page
- 1
- …
- 147
- 148
- 149
- 150
- 151
- …
- 188
- Next Page »